Redwood City, Calif.- based Dextera, formerly known as Cardica, agreed to the buyout in December 2017. The consummation Feb. 20 saw Dextera receive $13.6 million; another $2 million went into two-year escrow, $900,000 went to repay a loan from Aesculap and the balance was used to pay off contracts and leases and to settle closing expenses, according to a regulatory filing.
Aesculap said it plans to oversee operations in Redwood City, keeping Dextera’s products on the market as it looks to expand its footprint in the cardio-thoracic surgery market.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.